Aarkstore Market Research Report – Frontier Pharma Parkinsons Disease – Identifying and Commercializing First-in-Class Innovation

Aarkstore Market Research Report – Frontier Pharma: Parkinsons Disease – Identifying and Commercializing First-in-Class Innovation
SummaryLarge Degree of Innovation in Parkinsons Disease PipelineThe “Parkinsons disease” (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market relies on symptomatic treatments that target neuromodulatory receptors, the pipeline shows a diverse range of neuroprotective therapies targeting dysfunctional disease processes. This diversity is partially due to the presence of 90 first-in-class products, which accounts for 37% of the overall pipeline therapies that disclosed their target. In an industry, market and development landscape that favors first-in-class over non-first-in-class development in many ways, such as through faster approval or greater revenue, this finding has strategic implications for a wide array of market participants, both large and small. Despite their historically high attrition rate, first-in-class therapies that reach the market have the potential to transform and improve the PD treatment landscape.Alignment of First-in-Class Molecular Target with Disease Processes and GeneticsPD is a complex and multifaceted disease with a complex interplay between different pathological processes. Enormous research efforts and significant technological advances have furthered knowledge of the neuroanatomy of the basal ganglia and of the fundamental processes underlying neurodegeneration, helped by the ongoing identification of susceptibility genes and causative genes in familial PD. Although the exact mechanisms that initiate onset remain unclear, these insights have been translated into the pool of novel therapeutic…

Leave a Reply

© 2020 CreativeManagementNYC · Crumbs Theme by WPCrumbs